Boehringer Ingelheim and Abu Dhabi Join Forces for Precision Medicine

The Department of Health – Abu Dhabi (DoH) has formed a strategic alliance with the global biopharmaceutical leader Boehringer Ingelheim, aimed at expediting precision medicine research utilizing Abu Dhabi's forefront genomic technologies.

This agreement was formalized at the BIO International Convention 2026 held in San Diego. The partnership seeks to deepen scientific insight into the ways genetic factors contribute to disease progression and patient treatment responses.

Research Scope: Major and Rare Disease Focus

Throughout this collaboration, researchers will examine a wide spectrum of medical conditions. These will encompass cardiovascular diseases, diabetes, various cancers, rare conditions, neurological issues, metabolic disorders, fibrotic diseases, eye health, and immune-related ailments.

The outcomes from this research are anticipated to enhance understanding of disease mechanisms and pave the way for tailored treatment strategies for patients.

Leveraging Abu Dhabi's Genomic Infrastructure for Innovation

The partnership will utilize Abu Dhabi's genomic and biobank resources to derive scientific insights that prop up more efficient and personalized healthcare solutions.

By integrating cutting-edge genomic studies with healthcare data, this initiative aspires to bolster the future landscape of precision medicine and elevate patient care standards.

Dedication to Personalized Healthcare Underlined

Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi, emphasized that this partnership underscores the emirate's resolve in enhancing population health research and advancing personalized medicine.

She noted that this collaboration showcases Abu Dhabi's sustained commitment to leveraging scientific research and innovation to boost healthcare outcomes.

Boehringer's Mission to Address Medical Gaps

Boehringer Ingelheim affirmed that this partnership is essential for tapping into unmet medical needs by merging advanced research, data, and inventive solutions.

The company reiterated that this collaboration is specifically structured to enhance patient outcomes while fostering the future of healthcare across the UAE and the broader region.